-
Capital, M&A & Industry Strategy1 month agoBoomRay and Novartis Pharma sign $900m deal for radioligand therapy
The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net...
-
Capital, M&A & Industry Strategy1 month agoBoehringer and Envisagenics to develop precision cancer therapies
Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related...
-
Capital, M&A & Industry Strategy1 month agoBoehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.
-
Capital, M&A & Industry Strategy1 month agoUK issues £45m funding call for research partnerships
The NIHR has revealed the first £45m in funding for projects that can bridge the translation gap in healthcare, focusing initially on community care.
-
Capital, M&A & Industry Strategy1 month agoAstraZeneca recommits to youth health to dial funding past $100M
AstraZeneca has re-upped its UNICEF-partnered Young Health Programme, committing to a new five-year phase that will move total investment in the initiative above $100 million.
-
Capital, M&A & Industry Strategy1 month agoChina’s surging biotech sector represents both competition and lifeline for the US
As Chinese companies push beyond “me-too” drugs and the country lays out a new five-year plan targeting a $522 billion–strong biotech industry by 2030, experts say...
-
Capital, M&A & Industry Strategy1 month agoLed by the U.S. and China, radiopharma financing reaches new heights
BIOCENTURY | DATA BYTELED BY THE U.S. AND CHINA, RADIOPHARMA FINANCING REACHES NEW HEIGHTSTelix debt places Australia among leaders
-
Capital, M&A & Industry Strategy1 month ago2026 IPO blitz continues with 4 new biotech filings
With more than 25 companies debuting on the public markets, 2026 has recorded the highest number of biotech IPOs since 2021. Now, four companies—including Iambic Therapeutics...
-
Capital, M&A & Industry Strategy1 month agoNovo’s workforce reduction climbs to 13,000 to fuel R&D work
Novo CEO Maziar Mike Doustdar disclosed an additional 4,000 staff departures, which a spokesperson told BioSpace are linked to attrition and other measures.
-
Capital, M&A & Industry Strategy1 month agoBest Practices for Establishing Data Integrity in Western Blotting
Despite advances in other proteomic methods, including mass spectrometry, western blotting remains one of the most widely-used techniques across life sciences research due to its affordability,...
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
